BEZ235 daily with weekly Trastuzumab vs Lapatinib and Capecitabine.

• Research type

  Research Study

• Full title

  A phase Ib/randomized phase II study of BEZ235 and Trastuzumab versus Lapatinib and Capecitabine in patients with HER2 positive locally advanced or metastatic breast cancer who failed prior Trastuzumab

• IRAS ID

  90789

• Contact name

  Andrew Wardley

• Sponsor organisation

  Novartis Pharma S.A.S.

• Eudract number

  2011-003602-20

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  A phase Ib/randomized phase II study of BEZ235 and Trastuzumab versus Lapatinib and Capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who failed prior Trastuzumab. The study is a dose-finding phase Ib study followed by a randomized phase II study.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  11/SC/0506

• Date of REC Opinion

  21 Dec 2011

• REC opinion

  Further Information Favourable Opinion